Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer
Authors:
Abstract
Background: The CpG island methylator phenotype (CIMP or CIMP-high) with widespread promoter methylation is a distinct epigenetic phenotype in colorectal cancer. In contrast, a phenotype with less widespread promoter methylation (CIMP-low) has not been well characterised. O-6-methylguanine-DNA methyltransferase ( MGMT ) promoter methylation and silencing have been associated with G>A mutations and microsatellite instability-low (MSI-low). Aim: To examine molecular correlates with MGMT methylation/silencing in colorectal cancer. Methods: Utilising MethyLight technology, we quantified DNA methylation in MGMT and eight other markers (a CIMP-diagnostic panel; CACNA1G , CDKN2A (p16) , CRABP1 , IGF2 , MLH1 , NEUROG1 , RUNX3 and SOCS1 ) in 920 population-based colorectal cancers. Results: Tumours with both MGMT methylation and loss were correlated positively with MSI-low (p = 0.02), CIMP-high (⩾6/8 methylated CIMP markers, p = 0.005), CIMP-low (1/8–5/8 methylated CIMP markers, p = 0.002, compared to CIMP-0 with 0/8 methylated markers), KRAS G>A mutation (p = 0.02), and inversely with 18q loss of heterozygosity (p = 0.0002). Tumours were classified into nine MSI/CIMP subtypes. Among the CIMP-low group, tumours with both MGMT methylation and loss were far more frequent in MSI-low tumours (67%, 12/18) than MSI-high tumours (5.6%, 1/18; p = 0.0003) and microsatellite stable (MSS) tumours (33%, 52/160; p = 0.008). However, no such relationship was observed among the CIMP-high or CIMP-0 groups. Conclusion: The relationship between MGMT methylation/silencing and MSI-low is limited to only CIMP-low tumours, supporting the suggestion that CIMP-low in colorectal cancer may be a different molecular phenotype from CIMP-high and CIMP-0. Our data support a molecular difference between MSI-low and MSS in colorectal cancer, and a possible link between CIMP-low, MSI-low, MGMT methylation/loss and KRAS mutation.Keywords
This publication has 50 references indexed in Scilit:
- MGMT Promoter Methylation and Field Defect in Sporadic Colorectal CancerJNCI: Journal of the National Cancer Institute, 2005
- Morphology and microsatellite instability in sporadic serrated and non‐serrated colorectal cancerThe Journal of Pathology, 2005
- DNA Methylation, Field Effects, and Colorectal CancerJNCI: Journal of the National Cancer Institute, 2005
- Evaluation of a Large, Population-Based Sample Supports a CpG Island Methylator Phenotype in Colon CancerGastroenterology, 2005
- Serrated adenoma of the colorectum and the DNA-methylator phenotypeNature Clinical Practice Oncology, 2005
- Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability.2001
- Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis.2000
- MethyLight: a high-throughput assay to measure DNA methylationNucleic Acids Research, 2000
- Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotypeProceedings of the National Academy of Sciences, 2000
- Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways.Journal of Clinical Pathology, 1999